Ophthalmology

Short-Term Improvements Seen in Patients With nAMD Switching to Faricimab

May 14th 2025

A higher composite dietary antioxidant index was found to decrease the chances of American adults developing cataracts.

Screening for AMD | Image credit: RFBSIP - stock.adobe.com

FDA Delivers CRL for Longer Dosage Intervals in Aflibercept for DME, Wet AMD

May 1st 2025

Vision test | Image credit: Miroslav110 - stock.adobe.com

Sleep Disruptions Contribute to Likelihood of Dry Eye Syndrome

April 21st 2025

Man rubbing his eyes | Image credit: Prostock-studio - stock.adobe.com

Reproxalap Receives Complete Response Letter From FDA for Use in Dry Eye Disease

April 9th 2025

Dry eye | Image credit: Kryuchka Yaroslav - stock.adobe.com

April 3rd 2025

Continuing Medical Education

View All

1.5 Credits / Ophthalmology, Optometry

Application of Recent Data in Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: Managed Care Insights and Strategies

May 13, 2025 | 7:00 PM ET

Leveraging Novel Therapies to Transform Demodex Blepharitis Care

1.5 Credits / Ophthalmology/Optometry

Patient-Centered Treatment Plans for Management of Neovascular (Wet) AMD and Diabetic Macular Edema: Insights on Recent Efficacy, Safety, and Real-World Data to Improve Adherence and Outcomes

Leveraging Novel Therapies to Transform Demodex Blepharitis Care (6/11)

Jun 11, 2025 1:00 PM ET

Integrating Multi-Cancer Early Detection Tests Into Clinical Practice: The Health Economics Perspective for Managed Care Professionals

1.5 Credits / Oncology

1.5 Credits / Endocrinology, Diabetes & Metabolism, Ophthalmology/Optometry

The Evolving Strategies for Managing nAMD and DME: Empowering Managed Care Decisions for Improved Patient Outcomes

More News

October 23rd 2021

Ranibizumab Linked With Extensive Lapses in Care for Proliferative Diabetic Retinopathy

Approximately half of patients with proliferative diabetic retinopathy exhibited long lapses in care when prescribed ranibizumab across a 5-year follow-up.

October 21st 2021

Ophthalmology Overview: First Nasal Spray for Dry Eye Disease, Surgical Outcomes in Pediatric Patients, and More

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

October 14th 2021

Ophthalmology Overview: How Chronic Pain Impacts the Cornea, Dry Eye Disease in Postmenopausal Women, and More

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

October 11th 2021

Study Finds Significant Price Transparency Concerns for Ophthalmologic Procedures

An evaluation of price transparency tools for ophthalmologic procedures found significant usability, availability, and variability issues, which may disproportionately impact vulnerable populations.

October 7th 2021

Ophthalmology Overview: Novel Technology for Dry Eye Disease, Causes of Macular Degeneration, and More

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

October 5th 2021

Young-Onset Type 2 Diabetes Linked With Higher Risk of Retinopathy in Men

Male patients with young-onset type 2 diabetes were found to be at 72% greater risk of retinopathy compared with those who received a diagnosis at 50 years or older.

September 30th 2021

Ophthalmology Overview: Virtual Training for Diabetic Retinopathy, Impact of Blurry Vision, and More

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

September 28th 2021

Insulin Pump Use Linked With Decreased Risk of Diabetic Retinopathy in Young Patients With T1D

Risk of diabetic retinopathy (DR) was found to be decreased in young patients with type 1 diabetes (T1D) who were treated with insulin pumps, with findings also indicating a 2.1-fold greater risk of DR in Black participants compared with White individuals.

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision.

September 24th 2021

Dr Rajesh Rajpal on the Future of Eye Lens Technology, Cataract Surgery

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, addresses ongoing and future innovations in eye lens technology and instruments for cataract surgery.

September 20th 2021

Development of Myopia Found to Accelerate in Young Schoolchildren Amid Pandemic

Incidence and risk of myopia development were found to rise significantly among young Chinese schoolchildren who were exposed to environmental changes caused by COVID-19 between grades 2 to 3.

September 17th 2021

Ophthalmology Overview: Training With Virtual Reality, Refractive Error in Children, and More

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

September 15th 2021

Comorbid Ophthalmic, Systemic Conditions Linked With Higher Risk of Dementia

People with both ophthalmic and systemic conditions were found to be at higher risk of dementia compared with those with only 1 such condition. Some ophthalmic conditions—age-related macular degeneration, cataract, and diabetes-related eye disease—also increased risk on their own.

September 11th 2021

Dr Rajesh Rajpal Reviews Latest Innovations in Cataract Surgery

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses the surgical options available to patients undergoing cataract surgery.

September 10th 2021

School-Based Vision Program Shown to Improve Short-term Academic Performance in Adolescents

Students in grades 3 to 7 who were given eyeglasses as part of a school-based vision program were found to achieve better reading scores and exhibit improved academic achievement over 1 year.

September 2nd 2021

Ophthalmology Overview: Managing a Practice, Weight Loss Lessens Risk of Cataract, and More

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

August 31st 2021

Study Finds Increased Dosage of Timolol-Dorzolamide Fixed Combination Safe, Effective in Open-Angle Glaucoma

Increasing the dosage of timolol-dorzolamide fixed combination from twice a day to 3 times a day was found to be safe and significantly more effective in reducing intraocular pressure in patients with open-angle glaucoma, although further research on safety may be warranted.

Rajesh Rajpal, Johnson & Johnson Vision.

August 27th 2021

Dr Rajesh Rajpal on Eye Health Implications of Visual Needs in Younger Populations

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses how greater visual needs are contributing to adverse eye health in younger populations.

August 25th 2021

Study Finds Significant Glaucoma Surgery, Mortality Risk Link in Elderly Patients

Elderly patients who underwent surgery for glaucoma had a greater risk of all-cause and cause-specific mortality than those who did not have surgery, including greater risk of cancer and neurologic cause–related mortality.

August 24th 2021

Presurgery Corticosteroids May Worsen Conjunctival Hyperemia Post Trabeculectomy

Jared Kaltwasser

A new report suggests corticosteroids likely are not a panacea for ocular surface disease, a potential adverse effect of trabeculectomy.

August 21st 2021

Aflibercept Likely to Improve Severity, Complications of Nonproliferative Diabetic Retinopathy

Findings of the PANORAMA randomized clinical trial show that when patients with severe nonproliferative diabetic retinopathy were treated with intravitreal aflibercept, severity improved over 100 weeks and the likelihood of vision-threatening complications significantly reduced.

August 19th 2021

Low Safety Risk Observed in Office-Based, Operating Room Anti-VEGF Intravitreal Injections

A low risk of adverse safety outcomes was observed in anti–vascular endothelial growth factor (VEGF) intravitreal injections performed in office-based and operating room settings, with a higher rate of culture-positive endophthalmitis found in the office setting.

Rajesh Rajpal, MD, Johnson & Johnson Vision.

August 13th 2021

Dr Rajesh Rajpal Discusses Screen Usage, Eye Issues Amid the Pandemic

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, speaks on the impact of screen usage for eyes and trends in eye symptom burden reported amid the pandemic.

August 11th 2021

Ophthalmology Overview: Surge in Laser Vision Correction Procedures, Glaucoma Prevalence in West Africa, and More

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

August 7th 2021

Ophthalmology Overview: Bevacizumab BLA in Wet AMD, Long COVID-19 and Corneal Nerve Damage, and More

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

August 5th 2021

Aetna Requires Precertification for All Cataract Surgeries, Angering Ophthalmologists

Lauren Massaro

The health insurance provider said it believes up to 20% of all cataract surgeries may be unnecessary, but ophthalmology groups disagree.

July 31st 2021

Dr Rajesh Rajpal on US Prevalence of Cataracts, Risk Factors for Younger Populations

Rajesh Rajpal, MD, chief medical officer, global head of clinical medical affairs, Johnson & Johnson Vision, discusses the process of cataract development and its prevalence in both older and younger populations.

July 29th 2021

Ophthalmology Overview: 2022 Physician Fee Schedule Implications, Personalizing Glaucoma Surgery, and More

Highlighting the latest ophthalmology-related news reported across MJH Life Sciences™.

July 22nd 2021

Gene Therapy Associated With Vision Preservation in Retinal Disease

Lauren Massaro

The manipulation of key enzymes through methods of gene therapy was shown to provide protection against vision loss from multiple retinal conditions.

July 19th 2021

Dr Bobeck Modjtahedi Outlines Limitations of Telehealth Use for Diabetic Retinopathy

Gianna Melillo

Bobeck Modjtahedi, MD, highlights some of the challenges of using telehealth to treat individuals with diabetic retinopathy.

July 15th 2021

Ophthalmology Overview: Pediatric Eye Examinations, How Diet Affects Glaucoma, and More